SEMA3A and metabolic dysfunction-associated steatotic liver disease: In other words, while our report provides definitive evidence that SEMA3A in the microvascular endothelium promotes the early development of MASLD, understanding how SEMA3A affects systemic metabolism requires comprehensive investigations of other organs and cell types.